Business Wire

Dragonfly AI Lands £3m to Expedite Global Expansion

12.4.2022 14:19:00 EEST | Business Wire | Press release

Share

Dragonfly AI, the market leading predictive visual analytics platform, announced today that it has closed a £3m Series A funding round led by Guinness Ventures and existing investors Downing Ventures, while Capita PLC also participated in the round.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005628/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dragonfly AI (Photo: Business Wire)

Dragonfly AI has seen rapid growth in its customer portfolio which includes over 50 global brands including Diageo, GSK, and Vodafone. The new investment allows Dragonfly AI to further scale up its sales engine, build the client growth team and invest in an exciting behavioural science, R&D and product development roadmap. The funds will also be used to accelerate international expansion plans across Europe and North America.

Co-founded in 2018, by entrepreneurs Mark Bainbridge and David Mitchell, Dragonfly AI helps brands improve creative performance by accurately and instantly predicting what your audience sees first across any content, any channel.

Using the power of artificial intelligence and cutting-edge neuroscience technology, the easy -to-use technology provides real-time actionable insights, that helps marketers and insight teams make data-informed decisions, resulting in better informed creative decisions, performance marketing and improved sales performance.

Richard Mann, Chief Executive Officer at Dragonfly AI said: “We’re delighted to close this round of funding from investors that share our vision for the value that predictive technologies can bring to the creative design process. The investment will allow Dragonfly AI to continue scaling-up across Europe and the US. It will also allow us to invest more heavily in our technology platform, including initiatives such as the new e-commerce benchmarks that we are launching this quarter.”

Shane Gallwey, Head of Guinness Ventures said: “Dragonfly’s predictive visual tools are best in class, which is why leading global brands already use the technology to optimise their marketing. Our investment into Dragonfly brings another gem to the Guinness portfolio and we look forward to supporting their success as they scale-up their business.”

Richard Lewis, Partner at Downing Ventures said: “We are thrilled to be supporting Dragonfly in the next stage of its growth journey. It is a privilege to continue to support entrepreneurial teams that have developed world-class, innovative technology here at Downing. We look forward to continuing the good work with Dragonfly and assisting with its international expansion.”

Matt Bunn, Co-Founder and Managing Director at Capita Scaling Partner, added: “This represents a fantastic milestone for Dragonfly, and we are delighted to continue our support for the business. The company is on an exciting growth trajectory and continues to develop its world-leading product. We are looking forward to working closely with Guinness, Downing and the Dragonfly team to further expand its international client base.”

*Press Release Ends*

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kassandra McCalla
kassandra.mccalla@dragonflyai.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 09:00:00 EET | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne capability sensor for armasui

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 08:00:00 EET | Press release

Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201157212/en/ “We pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions. We’re excited about the potential to bring this innovative neuromodulator to the U.S., offering advanced performance and ease of use and building on our portfolio of neuromodulators that meets the full spectrum of injecto

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 09:00:00 EET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 19:27:00 EET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye